Stephens Investment Management Group LLC Has $63.36 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Stephens Investment Management Group LLC trimmed its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 9.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,752,068 shares of the specialty pharmaceutical company’s stock after selling 180,141 shares during the period. Stephens Investment Management Group LLC’s holdings in Supernus Pharmaceuticals were worth $63,355,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of SUPN. Barclays PLC boosted its holdings in Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after purchasing an additional 51,005 shares in the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter worth about $791,000. Geode Capital Management LLC increased its holdings in shares of Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after acquiring an additional 74,438 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after acquiring an additional 2,121 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Supernus Pharmaceuticals by 40.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company’s stock worth $7,901,000 after purchasing an additional 73,118 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SUPN. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cantor Fitzgerald started coverage on Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price on the stock.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $38.40 on Friday. The company has a market cap of $2.12 billion, a PE ratio of 35.89 and a beta of 0.90. The firm has a fifty day moving average price of $37.36 and a two-hundred day moving average price of $34.81. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Insider Activity

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.30% of the stock is owned by company insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.